Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-06-03Clinical Trial Update: SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease. [Phase 1]
Phase 1 trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI1814 in mild-to-moderate Alzheimer's disease pati…
-
FDA approval · 2019-05-31FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for memantine hydrochloride from Alembic Pharmaceuticals Limited, authorizing a generic version for …
-
CLINICAL_TRIALS trial_result · 2019-05-30Clinical Trial Update: Application of Amyloid PET in Cerebral Amyloid Angiopathy [Phase 3]
Phase 3 trial investigating the use of amyloid PET imaging in cerebral amyloid angiopathy has completed.
-
FDA approval · 2019-05-21FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for a generic donepezil hydrochloride product from Rising Pharma Holdings, Inc.
-
FDA approval · 2019-05-21FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Inc.)
The FDA approved a supplemental ANDA for donepezil hydrochloride, permitting a generic version of the Alzheimer's disease therapy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-05-21FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Dr. Reddys Laboratories Limited)
FDA approved a supplemental application for donepezil hydrochloride from Dr. Reddys Laboratories Limited. This action signifies regulatory a…
-
FDA approval · 2019-05-20FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for donepezil hydrochloride by Torrent Pharmaceuticals Limited.
-
FDA approval · 2019-05-20FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Cadila Pharmaceuticals Limited)
FDA approved Cadila Pharmaceuticals Limited's supplemental application for donepezil hydrochloride, a drug used to treat Alzheimer's disease…
-
FDA approval · 2019-05-20FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for donepezil hydrochloride, a generic Alzheimer's disease medication, submitted by Unichem Pharmace…
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) [Phase 3]
Phase 3 trial of verubecestat (MK-8931) in prodromal Alzheimer's disease and amnestic MCI was terminated with posted results.
-
FDA approval · 2019-04-23FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for donepezil hydrochloride, enabling a generic version of the Alzheimer's dise…
-
FDA approval · 2019-04-16FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for rivastigmine tartrate filed by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2019-04-16FDA Approved: RIVASTIGMINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for rivastigmine from Mylan Pharmaceuticals Inc. under ANDA 205622, updating the generic product's a…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease [Phase 2]
Phase 2 trial investigating intravenous immunoglobulin (IVIG) for cerebral and retinal amyloid in mild cognitive impairment due to Alzheimer…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging [Phase 4]
Phase 4 clinical trial update investigating early diagnosis and early treatment of Alzheimer's disease using senile plaque imaging.
-
FDA approval · 2019-04-04FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application from Aurobindo Pharma Limited for rivastigmine tartrate (generic), authorizing its use for treat…
-
CLINICAL_TRIALS research · 2019-03-29Clinical Trial Update: Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study [NA]
A completed pilot study on exercise in asymptomatic individuals at risk for Alzheimer’s disease prevention, with results posted.
-
CLINICAL_TRIALS trial_result · 2019-03-28Clinical Trial Update: Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) [Phase 2]
Phase 2 study investigating pimavanserin for agitation and aggression in Alzheimer's disease; the trial was terminated with results posted i…
-
FDA approval · 2019-03-21FDA Approved: RIVASTIGMINE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for rivastigmine by Amneal Pharmaceuticals LLC under ANDA207308.
-
CLINICAL_TRIALS trial_result · 2019-03-14Clinical Trial Update: Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer [Phase 4]
Phase 4 clinical trial comparing once daily versus twice daily memantine for safety and tolerability in Alzheimer dementia; results posted i…
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: Escitalopram Effects on CSF Amyloid Beta [Phase 4]
A Phase 4 clinical trial evaluated escitalopram's effects on cerebrospinal fluid amyloid beta levels; results have been posted after complet…
-
FDA approval · 2019-03-04FDA Approved: RIVASTIGMINE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves the original generic application for rivastigmine from Zydus Pharmaceuticals USA Inc., enabling the marketing of rivastigmine p…
-
CLINICAL_TRIALS trial_result · 2019-02-28Clinical Trial Update: [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001) [Phase 1]
Phase 1 PET tracer validation trial for [11C]MK-6884 in Alzheimer's disease has completed with results posted.
-
CLINICAL_TRIALS research · 2019-02-12Clinical Trial Update: The Efficacy of Traditional Chinese Herbal Medicine for Dementia [NA]
Clinical trial update on the efficacy of traditional Chinese herbal medicine for dementia. Current status is unknown.
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline [NA]
Completed feasibility trial evaluating a Mediterranean diet pattern to prevent cognitive decline in individuals with Alzheimer's disease or …